The role and price of brigatinib

Brigatinib (Brigatinib) is a targeted drug used to treat ALK (anaplastic lymphoma kinase) gene mutation-positive non-small cell lung cancer (NSCLC). As a second-generation tyrosine kinase inhibitor (TKI), brigatinib (brigatinib) has significant anti-tumor activity,

Brigatinib is now on the market in China and has been included in the medical insurance catalog. Patients can purchase it domestically at a price of about four to five thousand yuan. For specific price information and medical insurance reimbursement details, please consult your local hospital or pharmacy. In comparison, the prices of generic drugs in foreign markets are relatively low, especially those in Laos. The price is only a few hundred yuan, which is far lower than the domestic price, and the drug ingredients are basically the same as the original drugs.

The main mechanism of action of brigatinib is to interfere with the growth and spread of tumor cells by inhibiting the activity of ALK kinase. ALKGene mutations produce abnormal ALKkinase, which continuously activates tumor cell proliferation and survival signaling pathways. Brigatinib effectively interrupts the growth signal of cancer cells by binding to the ATP binding site of ALK kinase and preventing its phosphorylation activity. In addition to targeting ALK mutations, brigatinib (brigatinib) also has a certain inhibitory effect on certain ROS1 mutations.

Brigatinib has demonstrated significant clinical efficacy in the treatment of ALK mutation-positive non-small cell lung cancer. Clinical studies have shown that brigatinib can effectively delay tumor progression and improve the objective response rate in patients with ALK mutation-positive tumors. Particularly in patients who have developed resistance to first-line ALK inhibitors such as crizotinib, brigatinib has shown promising efficacy. Its drug design enables it to have better penetration into the central nervous system and can effectively control the growth of tumors that metastasize to the brain, which is especially important for patients with non-small cell lung cancer.

AlthoughBrigatinib is generally well tolerated, but it may cause side effects such as pneumonia, nausea, diarrhea, high blood sugar, and rash. Patients need regular monitoring while taking brigatinib so that these side effects can be detected and managed early. Doctors may adjust drug dosage or take symptomatic treatment measures based on the patient's specific conditions.